Mangoceuticals (MGRX) Q3 2025 earnings summary

Executive summary

• Focused on men's wellness via telemedicine, offering ED, hair loss, hormone, and weight management products, plus an FDA-approved testosterone therapy and new IP for respiratory illness prevention and skin care.

• Revenues declined year-over-year due to platform migration issues; significant increase in net loss driven by higher stock-based compensation and G&A expenses.

• Multiple new product launches, IP acquisitions, and master distribution agreements, with some agreements later rescinded.

• Ongoing strategic review for potential mergers, acquisitions, or other business combinations to maximize shareholder value.

Financial highlights

• Revenues for the nine months ended September 30, 2025, were $361,661, down from $510,626 year-over-year.

• Net loss for the nine months ended September 30, 2025, was $17,874,085, compared to $6,758,630 in the prior year period.

• Cash on hand as of September 30, 2025, was $481,281, up from $58,653 at December 31, 2024, due to financing activities.

• Stock-based compensation expense rose sharply to $10,753,217 for the nine months ended September 30, 2025.

• Working capital deficit of $0.2 million as of September 30, 2025.

Outlook and guidance

• Management anticipates the need for additional funding to continue operations and support growth over the next 12 months.

• Plans to expand organically and through acquisitions, with a focus on technology, health, and wellness sectors.

• No assurance of successful capital raising; potential for significant shareholder dilution if equity is issued.